May 8th 2024
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Duvelisib Granted Priority Review by FDA for CLL and Follicular Lymphoma
April 9th 2018A new drug application seeking a full approval for duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma has been granted a priority review by the FDA.
Read More
Expert Highlights Potential of Targeted Therapies in Combinations for CLL
April 5th 2018The treatment paradigm of chronic lymphocytic leukemia continues to advance, with many ongoing clinical trials investigating combinations seeking to build upon the success seen with Bruton’s tyrosine kinase inhibitors. Such potential combination therapies for CLL include venetoclax (Venclexta) with either ibrutinib (Imbruvica) or acalabrutinib (Calquence).
Read More
MURANO Trial Results Demonstrate PFS Benefit with Venetoclax/Rituximab
March 24th 2018According to findings from the phase III MURANO trial recently published in the<em> New England Journal of Medicine, </em>the venetoclax (Venclexta) plus rituximab (Rituxan) regimen lowered the risk of disease progression or death by 83% in comparison with bendamustine (Treanda) plus rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic leukemia<em>.</em>
Read More
A Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL
February 28th 2018Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the phase III DUO trial, a randomized comparison of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia.
Watch
Umbralisib Shows Encouraging Early Activity in CLL and Lymphoma
February 23rd 2018According to phase I findings published in <em>The Lancet Oncology,</em> an objective response rate of 37% was induced in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia treated with the PI3K-delta inhibitor umbralisib.
Read More
O'Brien Covers Evolution of Long-Term Data With Ibrutinib in CLL Landscape
February 15th 2018Susan O’Brien, MD, discusses the tremendous impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies and highlights where this regimen is headed in the future of treatment for patients with CLL.
Read More
Factors Affecting Prognosis and Treatment in CLL
February 15th 2018Based on improved insight into chronic lymphocytic leukemia biology and pathophysiology, approaches to identify patients who are at higher risk for disease progression have been refined, as have strategies to select therapies that maximize treatment outcomes due to their selectivity for distinctive phenotypic or physiological features of the respective CLL cells.
Read More
Emerging Treatment Strategies in CLL
February 14th 2018Prospects for patients with chronic lymphocytic leukemia have improved with the use of targeted agents such as ibrutinib; however, complete remissions are rare, and treatment options for patients relapsing after treatment with ibrutinib remain limited.
Read More
Current Approaches to Diagnosis and Risk Stratification in CLL
February 13th 2018Recent years have seen major advances in diagnostic approaches in CLL, and disease assessment may now include analysis of multiple genetic mutations in addition to recurrent cytogenetic changes. Furthermore, with the development of novel treatment approaches, the significance of prognostic markers is shifting.
Read More
Duvelisib Submitted for FDA Approval in CLL, Follicular Lymphoma
February 7th 2018Based on supporting data from the phase III DUO trial and the phase II DYNAMO study, duvelisib has been submitted to the FDA for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
Read More
A Phase II Study of Ibrutinib Plus FCR as Frontline Therapy in Younger CLL Patients
February 7th 2018Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a multicenter study of ibrutinib (Imbruvica) plus FCR as a frontline therapy for younger patients with chronic lymphocytic leukemia (CLL). <br />
Watch
Arsenic Trioxide Approved by FDA for Promyelocytic Leukemia
January 17th 2018Arsenic trioxide (Trisenox) has been approved by the FDA in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or <em>PML-RARA</em> gene expression.
Read More
Nilotinib Label for CML Updated by FDA With Discontinuation Provision
December 26th 2017The label for nilotinib (Tasigna) has been updated by the FDA with a provision stating patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) who have received the BCR-ABL tyrosine kinase inhibitor could be eligible to stop treatment after having recieved for at least 3 years and having achieved the specific predetermined criteria.<br /> <br />
Read More
Ibrutinib Plus Chemoimmunotherapy Demonstrates Promising Frontline Results in CLL
December 19th 2017In patients with chronic lymphocytic leukemia (CLL), the addition of ibrutinib to standard frontline chemoimmunotherapy induced negative minimum residual disease (MRD) status in bone marrow for 83% of patients, according to results from a preliminary clinical study presented at the 2017 ASH Annual Meeting.
Read More
The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL
December 13th 2017Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br />
Watch